Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects three bowel cancer drugs

The National Institute for Health and Clinical Excellence (NICE) has decided to not recommend three metastatic colorectal cancer drugs as they are not deemed cost effective

The National Institute for Health and Clinical Excellence (NICE) has rejected three drugs for the treatment of metastatic colorectal cancer, as they do not represent value for money.

NICE decided not to recommend Roche's Avastin, Merck KGaA's Erbitux and Amgen's Vectibix, as the high cost of the drugs could not be justified. The agency said that no convincing data was presented to demonstrate the extension of life for a patient with the disease.

NICE has currently recommended six treatments for the various stages of colorectal cancer, and commented that it was “disappointed not to be able to recommend” the three drugs.

Around 20-55 per cent of people with colorectal cancer have metastatic disease by the time of diagnosis.

The companies have been allowed to submit further comments on the committee's interpretation of their products, or consider reducing their prices.

5th September 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Pharma index map
The 2019 CPhI Pharma Index Report
Examining this year’s industry performance...
Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...

Infographics